MiniMed Shares Gain as 1Q Sales Jump
By Connor Hart
Shares of MiniMed Group climbed after the company reported higher sales in its fiscal first quarter, boosted by continued international growth and accelerating U.S. growth.
The stock rose 8.1%, to $21.91, on Tuesday. The company, which makes medical technology for diabetes patients, was spun off from Medtronic earlier this year.
MiniMed before the bell said it broke even in its three months ended July 31, compared with a loss of $19 million, or 8 cents a share, a year earlier.
Sales jumped 17% to $843 million, coming in ahead of the $826.8 million that analysts polled by FactSet expected. On an organic basis, sales were up 16%.
International sales totaled $603 million, up 18% from last year, while U.S. sales stood at $240 million, marking a 13% increase from a year ago.
Chief Executive Que Dallara called the quarter an excellent start to the fiscal year. "As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value," she added.
Looking ahead, MiniMed said it now expects organic revenue growth of about 10.5% for the year, up slightly from a prior forecast of roughly 10% growth.
The report came as Medtronic separately on Tuesday raised its outlook for the year and announced two separate investments totaling about $780 million--one supporting a heart-technology company, and the other a surgical-robotics company.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
September 01, 2026 11:18 ET (15:18 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
